University Hospitals Cleveland Medical Center chosen to test Pfizer/BioNTech COVID-19 vaccine

Editor's Note

The University Hospitals Cleveland Medical Center (UH) announced August 24 that it will participate as a study site for the Phase 2/3 global trial of the Pfizer/BioNTech investigational COVID-19 vaccine.

UH is one of approximately 120 clinical investigational sites around the world that will collectively enroll up to 30,000 participants.

The study is designed as a 1:1 vaccine, candidate to placebo, randomized, observer-blinded trial. The vaccine uses mRNA packaged with coronavirus genes to generate the spike protein, which is believed to generate protective antibodies.

UH is expecting shipment of the experimental vaccine and initiation of the trial in the next week. Those interested in participating in the UH study should call 612-524-9091 to learn more.